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Objectives: We evaluated the safety and effectiveness of the Resolute™ zotarolimus‐eluting stent (R‐ZES) in real‐
world clinical practice through 3 years.
Background: A randomized comparison of the R‐ZES and the XIENCE V™ everolimus‐eluting stent showed no
differencein anyoutcomes through3‐year follow‐upin high‐volume academic centers.RESOLUTEInternationalis
a conﬁrmatory trial designed to evaluate the R‐ZES in real‐world clinical practice.
Methods:RESOLUTEInternationalis asingle arm, observational trial thatenrolled 2,349 patients from88centers
with only a few inclusion and exclusion criteria. The primary end‐point was the composite of cardiac death and
target vessel myocardial infarction (TV‐MI) at 1 year. Secondary end‐points include target lesion failure (TLF),
target vessel revascularization (TVR), and their components, and stent thrombosis (ST).
Results:At3years97.2%ofpatientscompletedclinicalfollow‐up.Themeanagewas63.4 11.2years,77.8%were
male, and 30.4% had diabetes. The average numberof stents per patient was 1.6 1.0; and mean stent length was
30.9 20.5mm. Dual antiplatelet therapy was used in 91.1% of patients at 1 year, 43.0% at 2 years, and 34.6% at
3 years. Cardiac death and TV‐MI occurred in 161 patients (7.0%). There were 6 (0.3%) very late STevents for a
total STrate of 1.1% through 3 years. The rates of clinically driven target lesion revascularization (TLR), TVR, and
TLF were 5.7%, 7.4%, and 11.4%, respectively.
Conclusions: The safety and effectiveness of the R‐ZES through 3 years in this real‐world all‐comer study was
consistent with previously reported all‐comer trials. (J Interven Cardiol 2013;26:515–523)
Introduction
First generation drug‐eluting stents (DES) reduced
revascularization rates compared with bare metal stents
andbecamestandardofcareforthetreatmentoflesions
in coronary arteries.
1–4 Late (30 days to 1 year) and
very late (after 1 year) stent thrombosis (ST) was noted
in several studies and meta‐analyses, particularly when
theinclusioncriteria ofthesestudieswerebroadenedto
include more high‐risk patient and lesion character-
istics, and more diverse study centers.
5–11 DES were
redesigned to produce new generation devices with
improved polymer behavior and an expected lower rate
of ST.
12 Clinical trial results suggest that late and very
late ST rates are indeed lower with second‐ and third‐
generation DES,
13–17 although the studies lacked
power to reach deﬁnitive conclusions.
18 Data on
patients undergoing percutaneous coronary interven-
tion (PCI) and DES placement with clinical and lesion
characteristics reﬂective of routine clinical practice
have been limited. Recently, randomized trials evalu-
ating new DES have included broader patient
populations in order to better reﬂect routine clinical
practice.
13,14,19 These studies also obtained long‐term
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outcomes, including late and very late ST, in a patient
population reﬂective of real‐world settings. This report
describes the 3‐year clinical outcomes of patients
enrolled in the RESOLUTE International study.
Methods
Study Design and Patient Population. RESO-
LUTE International is 1 of the 5 studies included in
the RESOLUTE Global Clinical Trial Program. The
overall program has enrolled and treated 5,130 patients
with the Resolute™ zotarolimus‐eluting stent (R‐ZES;
Medtronic, Inc., Santa Rosa, CA, USA). All studies
have used similar data collection processes, end‐point
deﬁnitions, and evaluation and analytic methodolo-
gies.
14,15,20–24TheRESOLUTEInternationalstudyisa
prospective,multicenter,single‐arm studythatenrolled
2,349 patients from 88 sites in 17 countries worldwide,
between August 28, 2008 and March 19, 2009.
Detailed study methods and deﬁnitions have been
previously reported
23 and are summarized here. Key
inclusioncriteriawereageofatleast18years,coronary
lesion amenable to PCI with DES, and a signed
informed patient consent. Exclusion criteria were
limited to presence of pregnancy, inability to conform
to study procedures or required medications, and
participation in a concurrent trial. No restrictions were
placed on the number, size, or location of lesions or
vessels treated.
End‐points. The primary end‐point was the
composite of cardiac death or target vessel myocardial
infarction (TV‐MI) at 1 year. Secondary end‐points
included clinical safety and efﬁcacy outcomes through
2 years. Safety end‐points include cardiac death,
MI (Q‐wave and non‐Q wave), and deﬁnite and
probable ST as deﬁned by the Academic Research
Consortium (ARC).
11 Efﬁcacy end‐points included
target lesion revascularization (TLR), target lesion
failure (TLF; composite of cardiac death, TV‐MI,
or clinically driven TLR), and target vessel failure
(TVF; cardiac death, TV‐MI, or target vessel revascu-
larization [TVR]). Major adverse cardiac events (any
death, any MI, emergent coronary bypass grafting, or
TLR by percutaneous or surgical methods) were also
reported.
Deﬁnitions. End‐point deﬁnitions are similar for
all studies in the RESOLUTE Global Clinical
Program.
14,15,21,24 Cardiac death included any death
due to immediate cardiac cause (e.g., MI, low output
failure, fatal arrhythmia), any unwitnessed death or
death of unknown cause, and all procedure‐related
deaths including those related to concomitant treat-
ment. MIs were reported using the extended historical
deﬁnition for all‐comer studies.
25 Clinically driven
TLR or TVR included revascularization at the target
lesion (or vessel) associated with positive functional
ischemia study or ischemic symptoms and an angio-
graphic minimal lumen diameter stenosis  50%, or
revascularization of a target lesion (or vessel) with
diameter stenosis  70% without either angina or a
positive functional study. Patients were prospectively
deﬁned as being “complex” if they had at least 1 of
the following clinical or lesion characteristics: renal
insufﬁciency (serum creatinine  140mmol/L),
left ventricular ejection fraction <30%, acute MI
( 72hours), >1 lesion per vessel,  2 vessels stented,
lesions >27mm, bifurcations, bypass grafts, in‐stent
restenosis, unprotected left main, lesions with throm-
busortotalocclusion.Allotherpatientsweredeﬁnedas
“simple.” Lesion characteristics were assessed by
visual estimation only.
Study Procedures. The protocol encouraged all
investigatorstofollow theirsite‐speciﬁcproceduresfor
the treatment of patients undergoing PCI. Follow‐up in
clinic or telephonically occurred at 30 days, 6 months,
12 months, 24 months, and 36 months following the
index procedure. Pre‐ and postprocedural angiographic
parameters were visually estimated. The R‐ZES was
availableinthelengthsof8/9,12,14/15,18,24,30,and
38mm, and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, and
4.0mm. Recommended aspirin therapy included at
least75mgbeginning3dayspriortotheprocedure ora
preprocedure loading dose of at least 250mg, and a
daily dose of at least 75mg continued indeﬁnitely.
Recommended clopidogrel therapy included 75mg
for 3 days prior to the procedure, or a loading dose
of at least 300mg, with continued treatment at a daily
dose of 75mg for at least 6 months following the
procedure.
Event Adjudication. An independent Clinical
Events Committee (CEC; Cardiovascular Research
Foundation, New York, NY), comprising members not
involved in study operation or management, reviewed
all available documentation related to any serious
adverse event. Our study encouraged real‐world use of
the R‐ZES, and therefore did not use an angiographic
core laboratory. All angiograms associated with any
adverse event, along with any other supporting
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CEC for adjudication. In the case of any MI events, the
measurement of cardiac enzymes was based on center‐
speciﬁc procedures. As part of the RESOLUTE Global
Clinical Trial Program, the RESOLUTE International
study CEC activities were harmonized with the
RESOLUTE All Comers
14 and RESOLUTE US
studies
24 in order to ensure consistency in clinical
datareviewacrosstheentireclinicalprogram.AGlobal
Oversight Committee evaluated the consistency of
major cardiac adverse events (death, MI, TLR, TVR)
adjudication across the individual committees, and
provided recommendations; however, the RESOLUTE
International CEC’s decision was considered ﬁnal for
all events.
Study Management. Personnel trained to evalu-
ate clinical documentation visited each center at least
once to assess compliance and review all patient
consent forms. Personnel veriﬁed all source data for a
random sample of 25% of patients for 1‐year follow‐up
and approximately 20% of the patients for the 2‐year
and 3‐year follow‐up. Patients were classiﬁed as fully
monitored if all of their clinical source documentation
(including the consent form) and available records
associated with any adverse events were reviewed.
Theseprocedureswereconsistentwiththoseperformed
in well‐controlled, randomized trials. Patients were
classiﬁed as partially monitored if their consent form
and all available supporting records associated with
any adverse events were reviewed. Procedures were
also put in place to ensure data consistency and
accuracy. An electronic data capture system was used
to collect case report form data, which includes
automatic edit checks to minimize missing or eligible
data. The RESOLUTE International study was per-
formed according to the Declaration of Helsinki. Each
centers’ ethics committee or equivalent, if required,
approved the study protocol. Signed, informed consent
was obtained from each patient.
Statistical Analyses. Patients in whom the im-
plantation of at least 1 R‐ZES was attempted or
achieved comprise the intention‐to‐treat analyses
cohort. We prospectively planned to evaluate baseline
andeventdataforseveralsubgroups,includingpatients
with complex clinical and lesion characteristics and by
the extent of monitoring. Categorical variables are
presented as frequencies and percentages and continu-
ous variables are presented as means and standard
deviations. The Kaplan–Meier method was used to
calculate the cumulative incidence ﬁgures.
Results
Patient Data and Follow‐Up. At 3 years, 97.2%
of patients completed clinical follow‐up. The patient
baseline demographics have been previously re-
ported
23 and are shown in Table 1. The mean age
was 63.4 11.2 years, 77.8% of patients were male,
and 30.4% had diabetes mellitus. Prior PCI had been
performed in 29.6% of patients, and 8.4% underwent
prior coronary artery bypass grafting. A history of any
MI was reported in 27.0% of patients, and an acute MI
(AMI; <72hours) was present in 20%. Baseline lesion
and procedure characteristics are summarized in
Table 2. Most lesions were de novo (92.4%) with
57.1% in American College of Cardiology/American
Heart Association (ACC/AHA) class B2/C and 18.2%
bifurcated lesions. Multivessel treatment occurred in
14% of patients. Overall 67.5% of patients met the
deﬁnition for complex. The average number of stents
perpatientwas1.6 1.0withanaveragestentlengthof
30.9 20.5mm. Treated coronary arteries were left
Table 1. Patient Characteristics at Baseline
Total (n¼2,349)
Age, years 63.4 11.2
Men 77.8 (1,828)
Current smoker 24.3 (570)
Hyperlipidemia 63.9 (1,500)
Hypertension 68.0 (1,598)
Diabetes mellitus 30.4 (715)
Insulin treated 8.9 (210)
Prior myocardial infarction 27.0 (635)
Prior PCI 29.6 (696)
Prior coronary artery bypass
grafting
8.4 (197)
Acute coronary syndrome
Stable angina 37.4 (878)
Unstable angina 26.1 (612)
Acute myocardial infarction
(<72hours)
20.0 (469)
STEMI (<72hours) 10.7 (252)
Left ventricular ejection fraction
<30%
3.2 (50/1,545)
Serum creatinine (mmol/L) 90.07 38.45 (1,857)
Moderate/severe renal
impairment (creatinine
clearance
  <60mL/min)
18.9 (351/1,857)
All data presented as percentages (n) or mean standard deviation
(n). PCI, percutaneous coronary intervention; STEMI, ST elevation
myocardial infarction.
 Estimated using the Cockcroft‐Gault
formula.
31
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circumﬂex (27.5%).
Clinical Outcomes. Clinical outcomes through
3 years are shown in Table 3 and Figure 1. One‐year
outcomes are included for comparison. Cardiac death
or TV‐MI occurred in 161 patients (7.0%), and cardiac
death occurred in 82 (3.6%) patients through 3 years.
For the 89 (3.9%) patients who experienced a TV‐MI
event through 3 years, 69 were non‐Q wave. The rates
of clinically driven TLR and TVR were 5.7% and
7.4%, respectively. The composite end‐point of TLF
occurredin261(11.4%)patientsthrough3years.There
were 6 (0.3%) very late STevents for a total ST rate of
1.1% through 3 years (Fig. 2). The incremental event
rates from years 1 to 3 are shown in Table 3. Between
1‐ and 3‐year follow‐up there were 62 (2.8%) cardiac
death or TV‐MI events, 49 (2.2%) TLR events, and
6 (0.3%) ARC deﬁnite or probable ST events.
Clinical Outcomes by Select Subgroups. The
ratesofcardiacdeathandTV‐MIandTLRat3yearsfor
select subgroups are shown in Figure 3. Except for
patient groups known to be at higher risk, such as those
with diabetes mellitus, the rates of cardiac death and
TV‐MI in this all‐comer patient population were
generally consistent across the subgroups. The rates
of TLR across the subgroups were consistent across all
subgroups. Figure 4 shows the consistency in safety
and effectiveness outcomes at 3 years for all‐comer
Table 2. Lesion and Procedural Characteristics
Total (n¼2,349
patients,
3,148 lesions)
De novo lesions 92.4 (2,908)
ACC/AHA class B2/C lesions 57.1 (1,799)
Chronic total occlusion lesions 6.3 (199)
Bifurcation lesions 18.2 (573)
Preprocedure thrombus
  lesions 12.0 (378)
Patients with multiple vessels treated 14.0 (330)
Target vessel location, patients
Left main artery 2.6 (62)
Left anterior descending artery 51.0 (1,199)
Left circumflex artery 27.5 (646)
Right coronary artery 32.5 (764)
Bypass graft (SVGþarterial graft) 1.8 (42)
Reference vessel diameter, mm
  2.9 0.5
Minimum lumen diameter, mm
  0.5 0.4
Lesion length, mm
  18.8 10.8
 1 Small vessel (RVD 2.75mm) 45.4 (1,067)
Preoperative percent diameter stenosis 84.48 12.14
Lesions treated per patient 1.3 0.7
Stents per patient 1.6 1.0
Stent length per patient 30.9 20.5
Patients with  3 stents 14.3 (337)
All data presented as percentages (n) or mean standard deviation
(n). ACC/AHA, American College of Cardiology/American Heart
Association; RVD, reference vessel diameter; SVG, saphenous vein
graft.
 By visual estimation.
Table 3. Clinical Outcomes Through 3 Years Follow‐Up
1 Year
(n¼2,337)
3 Year
(n¼2,284)
Difference (%) Between
Year 1 and Year 3 and 95% CI
Cardiac death or TV‐MI
  4.2 (99) 7.0 (161)  2.8 ( 4.1,  1.5)
Death 2.4 (57) 6.1 (139)  3.6 ( 4.8,  2.5)
Cardiac death 1.5 (34) 3.6 (82)  2.1 ( 3.0,  1.2)
TV‐MI
  3.0 (71) 3.9 (89)  0.9 ( 1.9, 0.2)
Q‐wave 0.5 (12) 0.9 (20)  0.4 ( 0.8, 0.1)
Non‐Q wave 2.5 (59) 3.0 (69)  0.5 ( 1.4, 0.5)
Clinically driven TLR 3.5 (81) 5.7 (130)  2.2 ( 3.4,  1.0)
Clinically driven TVR 4.2 (99) 7.4 (168)  3.1 ( 4.5,  1.8)
TLF 7.1 (165) 11.4 (261)  4.4 ( 6.0,  2.7)
TVF 7.7 (180) 12.9 (294)  5.2 ( 6.9,  3.4)
ARC definite/probable stent thrombosis (all) 0.9 (20) 1.1 (26)  0.3 ( 0.9, 0.3)
Early (<30 days) 0.7 (17) 0.7 (17) NA
Late (31–360 days) 0.1 (3) 0.1 (3) NA
Very late (361–1,080 days) NA 0.3 (6) NA
All data presented as percentages (number of events) unless otherwise noted. ARC, Academic Research Consortium; NA, not applicable; TLF,
target lesion failure; TLR, target lesion revascularization; TVF, target vessel failure; TVR, target vessel revascularization.
 Target vessel
myocardial infarction: any myocardial infarction that occurs in a territory of a coronary artery that cannot be attributed with certainty to any other
vessel than the target vessel.
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3‐YEAR OUTCOMES FROM RESOLUTE INTERNATIONALpatients from the RESOLUTE All Comers trial and the
RESOLUTE International trial. Overall DAPT usage
remained high through 1 year postprocedure and
dropped to 43% in year 2 and 34.6% in year 3. DAPT
adherence remained high through 3 years in India but
decreased in Western Europe and the remaining
countries (Table 4).
Discussion
Extended 3‐year follow‐up of this large cohort of
patients from the RESOLUTE International study
further establishes the long‐term safety and efﬁcacy of
the R‐ZES and contributes to the growing body of
clinicalevidencefromtheRESOLUTEGlobalClinical
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Figure 3. Three‐year rates of cardiac death and myocardial infarction and clinically driven target lesion revascularization for select subgroups.
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outcomes for 2,349 patients, with only a few inclusion
and exclusion criteria, from 88 study centers, which
provided a broad patient cohort for evaluating R‐ZES
performance. Three‐year clinical follow‐up was com-
pleted for 97.2% of patients. The composite of cardiac
death and TV‐MI at 3 years was 7.0% and is
comparabletoratesreportedfromothernewgeneration
DES all‐comer trials.
14,26,27 The CEC adjudicated
deathsusingtheARCcriteria
11(i.e.,thetotalnumberof
cardiac deaths) includes those that were classiﬁed as
unknown.Ofthe48cardiacdeathsthatoccurredduring
the 2nd and 3rd years of follow‐up, 27 were due to
unknown causes. Three‐year cardiac mortality (3.6%)
in the RESOLUTE International Study was neverthe-
less similar to that reported by the RESOLUTE All
Comers and LEADERS trials.
15,28 Safety end‐points
occurred at low rates. The overall rate of TV‐MI in
RESOLUTE International was lower than the 3‐year
rates from the RESOLUTE All Comers trial (5.2%)
and LEADERS trial (7.0% for the biolimus‐eluting
stent [BES]).
14,28 The 3‐year TLR rate and modest
accrual of events between years 1 and 3 was consistent
with that observed in the RESOLUTE All Comers trial
(6% with R‐ZES and 5.8% with EES at 3 years)
14 and
other new generation DES.
28 TLR rates were also
consistent across various subgroups (Fig. 3), including
high‐risk complex patients and those with diabetes
mellitus. Among the 3‐year RESOLUTE International
cohort, there were only 6 (4 deﬁnite and 2 probable)
very late (361–1,080 days) ARC deﬁnite or probable
ST events for a rate of 0.3%. These low rates are
consistent with data reported from the RESOLUTE
All Comers trial (late: R‐ZES 0.6% and EES 0.2%;
very late: R‐ZES 0.5% and EES 0.5%),
14,15 and other
new generation DES such as the BES (late, 0.6%; very
late, 0.2%).
26
There was a higher adherence to DAPT at 2‐ and
3‐year follow‐up (43.0% and 34.6%, respectively)
compared with other all‐comer trials (18% at 2 years in
the RESOLUTE All Comers trial) but it is unclear
whether there is any impact on very late STrates in the
present study. Analysis of DAPT adherence by
geographic region (Table 4) suggests that prolonged
use of DAPT varies regionally, use is most likely
affected by numerous clinical and socioeconomic
confounders, and there is uncertainty regarding the
balance of risk and beneﬁt of longer versus shorter
DAPT use.
These results should be interpreted in the context of
the following limitations. The overall, mean accrual
rate per site was low in our study (3–4 patients per
month). At the time of study initiation, R‐ZES was a
new device. There may, therefore, have been a bias
against use of the stent, particularly because there were
other DES available at that time. Although it has been
suggested that underreporting of adverse events could
occur more often in observational studies, we believe
that the consistency of outcomes with previous R‐ZES
trials and numerous trial procedures conﬁrm the
validity of our results. These procedures included
database self‐checks and an independent CEC. We did,
however, observe an apparently lower rate of
TV‐MI events in RESOLUTE International than in
RESOLUTE All Comers (Fig. 4). This apparent
difference may have been driven by underreporting
of non‐Q‐wave events, which are more likely to be
missed in long‐term follow‐up than Q‐wave MIs.
In order to perform studies that mimic real‐world
practice asmuchaspossible,treatmentshouldbebased
on institution‐speciﬁc procedures, typically based on
expert‐driven guidelines
29,30 as was recommended in
the RESOLUTE International study. Each investiga-
tional site was encouraged to treat patients presenting
for PCI using the same standard procedures applied to
patients nottreated within aclinicaltrial. Therefore, we
believethattheeventratesfollowingtreatmentwiththe
R‐ZES in our study closely represent real‐world use of
Table 4. Dual Antiplatelet Therapy
  Adherence by Geographic Region
30‐Day (%) 6 Months (%) 1 Year (%) 2 Years (%) 3 Years (%)
Western Europe
† (n¼1,929) 97.4 95.7 90.5 39.5 28.7
India (n¼174) 97.7 97.7 98.8 97.6 98.2
Rest of world
‡ (n¼248) 96.4 95.5 90.5 39.2 31.7
Overall 97.5 95.9 91.1 43.0 34.6
 Aspirin and clopidogrel or ticlopidine.
†Austria, Belgium, Finland, Germany, the Netherlands, Norway, Portugal, Spain, Switzerland, United
Kingdom.
‡Argentina, Czech Republic, Estonia, Greece, Slovak Republic, South Africa.
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3‐YEAR OUTCOMES FROM RESOLUTE INTERNATIONALthe stent. The post hoc analyses evaluating DAPT
interruptionandSTwereexploratoryandlimitedbythe
small number of observed events.
Conclusion
The 3‐year clinical outcomes in this unrestrictive,
diverse, real‐world patient trial conﬁrm the long‐term
safety and effectiveness of the R‐ZES for the treatment
of single or multivessel obstructive coronary artery
disease. Safety and effectiveness outcomes were
similar to rates observed with other new generation
DES studies, including ﬁndings from the RESOLUTE
Global Clinical Program.
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